SP today, page-79

Oh and for anyone who didn't follow the link or who read the report but forgot, or those who have never read it, here is an important thing to remember.

Lest not forget that Dendreon's Provenge achieved an overall response rate of 16%. the medical community will consider anything over 10% as remarkable.

Cvac achieved 19% !!

You be blind not to notice the medical world and bio-investment world's hype about Provenge with forecasts of it hitting $50 in a month or two.

Cvac is proven so far. It will further prove itself. Let's put it this was, based on data so far and data from the Provenge trials at same stage, there's every reason to be more optimistic.

The FDA like what they saw with Provenge, despite the 2-year delay glitch which got many groups up in arms about, not least patients.